- Home
- CAPR vs LEGT Comparison
CAPR vs LEGT Comparison
Compare CAPR & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- LEGT
- Stock Information
- Founded
- CAPR 2005
- LEGT 2023
- Country
- CAPR United States
- LEGT United States
- Employees
- CAPR N/A
- LEGT N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- LEGT
- Sector
- CAPR Health Care
- LEGT
- Exchange
- CAPR Nasdaq
- LEGT Nasdaq
- Market Cap
- CAPR 324.6M
- LEGT 276.8M
- IPO Year
- CAPR N/A
- LEGT 2024
- Fundamental
- Price
- CAPR $6.08
- LEGT $10.74
- Analyst Decision
- CAPR Strong Buy
- LEGT
- Analyst Count
- CAPR 8
- LEGT 0
- Target Price
- CAPR $24.75
- LEGT N/A
- AVG Volume (30 Days)
- CAPR 1.2M
- LEGT 21.8K
- Earning Date
- CAPR 11-12-2025
- LEGT 01-01-0001
- Dividend Yield
- CAPR N/A
- LEGT N/A
- EPS Growth
- CAPR N/A
- LEGT N/A
- EPS
- CAPR N/A
- LEGT 0.35
- Revenue
- CAPR $13,392,150.00
- LEGT N/A
- Revenue This Year
- CAPR N/A
- LEGT N/A
- Revenue Next Year
- CAPR $7,894.07
- LEGT N/A
- P/E Ratio
- CAPR N/A
- LEGT $30.68
- Revenue Growth
- CAPR N/A
- LEGT N/A
- 52 Week Low
- CAPR $4.59
- LEGT $10.18
- 52 Week High
- CAPR $23.40
- LEGT $10.86
- Technical
- Relative Strength Index (RSI)
- CAPR 40.13
- LEGT 50.08
- Support Level
- CAPR $5.97
- LEGT $10.75
- Resistance Level
- CAPR $6.57
- LEGT $10.74
- Average True Range (ATR)
- CAPR 0.38
- LEGT 0.01
- MACD
- CAPR 0.03
- LEGT 0.00
- Stochastic Oscillator
- CAPR 36.70
- LEGT 33.33
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.